In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 201 to 250 of 374

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [TSID12203]	Technology appraisal guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance	9 September 2026
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain	HealthTech guidance	TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance	TBC
Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]	Technology appraisal guidance	TBC
Nirogacestat for treating desmoid tumours [ID6453]	Technology appraisal guidance	5 August 2026
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]	Technology appraisal guidance	17 July 2024
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]	Technology appraisal guidance	TBC
Nivolumab in combination for untreated advanced classical Hodgkin lymphoma in people 12 years and over [ID6690]	Technology appraisal guidance	TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]	Technology appraisal guidance	TBC
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]	Technology appraisal guidance	11 November 2026
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]	Technology appraisal guidance	TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]	Technology appraisal guidance	TBC
Non-invasive skin closure devices for surgical incisions (MT775)	Medical technologies guidance	TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]	Technology appraisal guidance	TBC
NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]	Technology appraisal guidance	TBC
Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519]	Technology appraisal guidance	14 October 2026
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]	Technology appraisal guidance	13 May 2027
Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management	NICE guideline	16 February 2027
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]	Technology appraisal guidance	19 August 2026
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]	Technology appraisal guidance	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Orforglipron for managing overweight and obesity [ID6516]	Technology appraisal guidance	18 November 2026
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]	Technology appraisal guidance	TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)	NICE guideline	29 July 2026
Oveporexton for treating type 1 narcolepsy [ID6622]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	23 July 2026
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]	Technology appraisal guidance	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis [TSID10594]	Technology appraisal guidance	TBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]	Technology appraisal guidance	TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]	Technology appraisal guidance	29 October 2026
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6473]	Technology appraisal guidance	TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	18 November 2026
Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607]	Technology appraisal guidance	10 February 2027
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]	Technology appraisal guidance	TBC

Results per page

10
25
50
All